Merck's Phase 3 enlicitide trial for hyperlipidemia recruiting in India
A single-site Phase 3 study of enlicitide decanoate (MK-0616) for high cholesterol in India is recruiting, with enrollment estimated at 150 participants.
Merck Sharp & Dohme's weekly update centers on a Phase 3 trial of enlicitide decanoate conducted in India.
- A Phase 3, randomized, placebo-controlled study (NCT07821944) is testing enlicitide decanoate, also called enlicitide or MK-0616, in adults with hyperlipidemia and hypercholesterolemia. Enlicitide is described as being in a class of medicines designed to lower low-density lipoprotein cholesterol (LDL-C).1 The trial was first posted on 2026-09-16 and last updated on 2026-10-22, and is currently recruiting at one site in Belagavi, Karnataka, India. The study has an estimated enrollment of 150 participants.1 Participants receive oral enlicitide decanoate or placebo, with the primary outcome measuring mean percent change in LDL-C from baseline at Week 24.1 Notably, the exclusion criteria bar patients previously treated with certain other cholesterol-lowering medications, including PCSK9 inhibitors1, indicating enlicitide is being studied as a distinct option from that drug class.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.